Literature DB >> 20308471

Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans.

Sophie E Rowbotham1, Nicola A Illingworth, Ann K Daly, Gareth J Veal, Alan V Boddy.   

Abstract

13-cis Retinoic acid (13cisRA, isotretinoin) is an important drug in both dermatology, and the treatment of high-risk neuroblastoma. 13cisRA is known to undergo cytochrome P450-mediated oxidation, mainly by CYP2C8, but phase II metabolic pathways have not been characterized. In the present study, the glucuronidation activities of human liver (HLM) and intestinal microsomes (HIM), as well as a panel of human UDP-glucuronosyltransferases (UGTs) toward both 13cisRA and the 4-oxo metabolite, 4-oxo 13cisRA, were compared using high-performance liquid chromatography. Both HLM and, to a greater extent, HIM catalyzed the glucuronidation of 13cisRA and 4-oxo 13cisRA. Based on the structures of 13cisRA and 4-oxo 13cisRA, the glucuronides formed are conjugated at the terminal carboxylic acid. Further analysis revealed that UGT1A1, UGT1A3, UGT1A7, UGT1A8, and UGT1A9 were the major isoforms responsible for the glucuronidation of both substrates. For 13cisRA, a pronounced substrate inhibition was observed with individual UGTs and with HIM. UGT1A3 exhibited the highest rate of activity toward both substrates, and a high rate of activity toward 13cisRA glucuronidation was also observed with UGT1A7. However, for both substrates, K(m) values were above concentrations reported in clinical studies. Therefore, UGT1A9 is likely to be the most important enzyme in the glucuronidation of both substrates as this enzyme had the lowest K(m) and is expressed in both the intestine and at high levels in the liver.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308471     DOI: 10.1124/dmd.109.031625

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Loss of PBRM1 Alters Promoter Histone Modifications and Activates ALDH1A1 to Drive Renal Cell Carcinoma.

Authors:  David A Schoenfeld; Royce Zhou; Sakellarios Zairis; William Su; Nicole Steinbach; Deepti Mathur; Ankita Bansal; Alexis L Zachem; Bertilia Tavarez; Dan Hasson; Emily Bernstein; Raul Rabadan; Ramon Parsons
Journal:  Mol Cancer Res       Date:  2022-08-05       Impact factor: 6.333

2.  Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.

Authors:  Gareth J Veal; Julie Errington; Sophie E Rowbotham; Nicola A Illingworth; Ghada Malik; Michael Cole; Ann K Daly; Andrew D J Pearson; Alan V Boddy
Journal:  Clin Cancer Res       Date:  2012-10-19       Impact factor: 12.531

3.  Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.

Authors:  N A Illingworth; A V Boddy; A K Daly; G J Veal
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

4.  Inter-isoform Hetero-dimerization of Human UDP-Glucuronosyltransferases (UGTs) 1A1, 1A9, and 2B7 and Impacts on Glucuronidation Activity.

Authors:  Ling-Min Yuan; Zhang-Zhao Gao; Hong-Ying Sun; Sai-Nan Qian; Yong-Sheng Xiao; Lian-Li Sun; Su Zeng
Journal:  Sci Rep       Date:  2016-11-18       Impact factor: 4.379

5.  Bioinformatic Analysis of Gene Variants from Gastroschisis Recurrence Identifies Multiple Novel Pathogenetic Pathways: Implication for the Closure of the Ventral Body Wall.

Authors:  Víctor M Salinas-Torres; Hugo L Gallardo-Blanco; Rafael A Salinas-Torres; Ricardo M Cerda-Flores; José J Lugo-Trampe; Daniel Z Villarreal-Martínez; Laura E Martínez de Villarreal
Journal:  Int J Mol Sci       Date:  2019-05-09       Impact factor: 5.923

6.  Multi-species transcriptome meta-analysis of the response to retinoic acid in vertebrates and comparative analysis of the effects of retinol and retinoic acid on gene expression in LMH cells.

Authors:  Clemens Falker-Gieske; Andrea Mott; Sören Franzenburg; Jens Tetens
Journal:  BMC Genomics       Date:  2021-03-02       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.